Martin Wermke

Also affiliated with Helmholtz-Zentrum Dresden-Rossendorf, University Hospital Heidelberg, Ford (Germany), National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Klinik und Poliklinik für Psychotherapie und Psychosomatik, Hochschule für Technik und Wirtschaft Dresden – University of Applied Sciences, Nationales Centrum für Tumorerkrankungen Dresden, Technische Universität Dresden

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia”.

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Blood(2020)10.1182/blood.2020007732

N/A

4.0DataRank · unranked

322 citations

Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt, Anjali S. Advani +43 more

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008668

N/A

0.742DataRank · unranked

29 citations

Tobias A.W. Holderried, Jason J. Luke, Van K. Morris, Winfried Alsdorf, Katrin Wetzko +27 more

794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors

(2020)10.1136/jitc-2020-sitc2020.0794

N/A

0DataRank · unranked

4 citations

Caroline Gaudy‐Marqueste, Martin Wermke, Antoîne Italiano, Emanuela Romano, Aurélien Marabelle +7 more

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

Leukemia(2021)10.1038/s41375-021-01328-9

N/A

0DataRank · unranked

183 citations

Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font, Rami S. Komrokji +35 more

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

American Journal of Hematology(2023)10.1002/ajh.27161

N/A

0DataRank · unranked

48 citations

Jordi Esteve, Kimmo Porkka, Steven Knapper, Elie Traer, Sebastian Scholl +22 more

1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma

Annals of Oncology(2024)10.1016/j.annonc.2024.08.1170

N/A

0DataRank · unranked

4 citations

James W. Smithy, Christy Los, Hannah L. Kalvin, Nathan Hasson, R. Amaria +15 more